These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25964685)

  • 1. Risk Factors for and Outcomes of Bacteremia Caused by Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella Species at a Canadian Tertiary Care Hospital.
    Nguyen ML; Toye B; Kanji S; Zvonar R
    Can J Hosp Pharm; 2015; 68(2):136-43. PubMed ID: 25964685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
    Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
    Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.
    Lee SY; Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    Infect Control Hosp Epidemiol; 2006 Nov; 27(11):1226-32. PubMed ID: 17080381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
    Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.
    Song KH; Jeon JH; Park WB; Park SW; Kim HB; Oh MD; Lee HS; Kim NJ; Choe KW
    BMC Infect Dis; 2009 Apr; 9():41. PubMed ID: 19361340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
    Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
    Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection.
    MacVane SH; Tuttle LO; Nicolau DP
    J Hosp Med; 2014 Apr; 9(4):232-8. PubMed ID: 24464783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee CH; Su LH; Chen FJ; Tang YF; Chien CC; Liu JW
    Clin Microbiol Infect; 2015 Dec; 21(12):1105.e1-8. PubMed ID: 26271718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Bilker WB; Lautenbach E
    Arch Intern Med; 2005 Jun; 165(12):1375-80. PubMed ID: 15983286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in intensive care units in Thailand.
    Assawatheptawee K; Kiddee A; Na-Udom A; Wangteeraprasert A; Treebupachatsakul P; Niumsup PR
    J Infect Chemother; 2021 Feb; 27(2):401-405. PubMed ID: 33132043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species.
    Han JH; Bilker WB; Nachamkin I; Zaoutis TE; Coffin SE; Linkin DR; Hu B; Tolomeo P; Fishman NO; Lautenbach E
    Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1160-6. PubMed ID: 24113599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-Spectrum β-Lactamase-Producing
    Chen J; Allel K; Zhuo C; Luo W; He N; Yang X; Guo Y; Wang J; Yao L; Li J; Lin Y; Tu R; Yakob L; Zhuo C
    Risk Manag Healthc Policy; 2024; 17():375-385. PubMed ID: 38434551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: a retrospective cohort study.
    Kim MJ; Song KH; Kim NH; Choe PG; Park WB; Bang JH; Kim ES; Park SW; Kim HB; Lee HS; Oh MD; Kim NJ
    Hepatol Int; 2014 Oct; 8(4):582-7. PubMed ID: 26202763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.